Trial Profile
A Study to Evaluate the Safety and Efficacy of Everolimus in Patients with Advanced Neuroendocrine Tumours (NET)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2015 New trial record